Reuters logo
7 months ago
BRIEF-Eagle Pharmaceuticals reports positive results from animal study supporting efficacy of RYANODEX for exertional heat stroke
December 13, 2016 / 12:12 PM / 7 months ago

BRIEF-Eagle Pharmaceuticals reports positive results from animal study supporting efficacy of RYANODEX for exertional heat stroke

1 Min Read

Dec 13 (Reuters) - Eagle Pharmaceuticals Inc :

* Eagle Pharmaceuticals inc - we anticipate completing NDA filing as soon as possible for RYANODEX

* Eagle Pharmaceuticals reports positive results from pivotal animal study supporting the efficacy of RYANODEX for exertional heat stroke

* Robust and clinically meaningful treatment difference in favor of RYANODEX was statistically significant

* Eagle pharmaceuticals - eagle could be first to market with a potentially life-saving treatment for EHS, if approved by FDA, as early as mid-2017

* Eagle Pharmaceuticals - clinical and nonclinical components of development program provide adequate safety, efficacy data to complete our NDA submission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below